BRAF and non-small cell lung carcinoma: Data on several other mutated NSCLC groups are still mostly inconclusive; some findings seem to suggest some benefits with ICIs in the case of pre-treated patients with HER2, BRAF, RET, and MET mutations, similar to those observed in unselected patients [47,48], while other studies suggest a poor benefit from ICIs in both pre-treated [49] and treatment-naïve patients [50].